Background/Aims: The prevalence of occult HBV infection depends on the prevalence of HBV infection in the general population. Hemodialysis patients are at increased risk for HBV infection. The aim of this study was to determine the prevalence of occult HBV infection in hemodialysis patients. Methods: Total of 98 patients undergoing hemodialysis in CHA Bundang Medical Center (Seongnam, Korea) were included. Liver function tests and analysis of HBsAg, anti-HBs, anti-HBc and anti-HCV were performed. HBV DNA testing was conducted by using two specific quantitative methods. Results: HBsAg was detected in 4 of 98 patients (4.1%), and they were excluded. Among 94 patients with HBsAg negative and anti-HCV negative, one (1.1%) patient with the TaqMan PCR test and 3 (3.2%) patients with the COBAS Amplicor HBV test were positive for HBV DNA. One patient was positive in both methods. Two patients were positive for both anti-HBs and anti-HBc and one patient was negative for both anti-HBs and anti-HBc. Conclusions: The present study showed the prevalence of occult HBV infection in HBsAg negative and anti-HCV negative patients on hemodialysis at our center was 3.2%. Because there is possibility of HBV transmission in HBsAg negative patients on hemodialysis, more attention should be given to prevent HBV transmission. (Korean J Gastroenterol 2013;61:209-214) 
INTRODUCTION
Chronic HBV infection is characterized by persistent detection of HBsAg and HBV DNA for 6 or more months after acute infection. [1] [2] [3] It is known that the clearance of HBsAg in patients with HBV infection is associated with the disappearance of HBV DNA and active viral replication.
However, several studies revealed that low levels of HBV DNA still remain detectable in the serum or liver tissue of some pa- formed according to the protocol previously described. 13, 14 Linear dynamic range of detection in the COBAS Amplicor HBV monitor test and TaqMan PCR test was found to be 300-2×10 5 copies/mL and 120-1.2×10 10 copies/mL, respectively.
Statistical analysis
IBM SPSS Statistics 19.0 (IBM Co., Armonk, NY, USA) was used for the statistical analysis. All data are expressed as means±standard deviation or median and range in continuous variables and percentage in categorized variables.
Mann-Whitney test and Fisher's exact test were used for comparing variables between HBV DNA positive patients and negative patients. All p-values less than 0.05 were considered statistically significant.
